Garris CS et al. also found that tumor-infiltrating DCs, a class of immune cells that do not respond to PD-1 antibodies, could promote the therapeutic effects of ICIs by responding to the IFN-γ signals released by neighboring T cells and releasing cytokines such as IL-12 (Figure 2C) [106]. This evidence concerns the gene IFNG and neoplasm.